APPENDIX

Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study)

Taku Kinoshita, Masahiro Shinoda, Yasuhiro Nishizaki, Katsuya Shiraki, Yuji Hirai, Yoshiko Kichikawa, Kenji Tsushima, Masaharu Sinkai, Naoyuki Komura, Kazuo Yoshida, Yasutoshi Kido, Hiroshi Kakeya, Naoto Uemura, Junichi Kadota

Contents

	Page
IRB information	1
Sample size calculation	2
Table S1. Discontinuation criteria	4
Table S2. Ordinal scale of severity	5
Table S3. Events and reasons for censoring patients for the analysis of time to SARS-CoV-2 negativity	6
Table S4. Events and reasons for censoring patients in the sensitivity analysis of the time to SARS-CoV-2 negativity	7
Table S5. Changes to the statistical analyses plan from the protocol	8
Table S6. Patient disposition	9
Table S7. Results of the sensitivity analysis of the primary endpoint	10
Table S8. Time to negative SARS-CoV-2 status as measured by the central laboratory	11
Table S9. Results of the subgroup analyses of time to negative SARS-CoV-2 status	12
CONSORT Checklist	14

IRB Information

The protocol and patient consent forms were reviewed and approved by the following institutional review boards or ethics committees at each participating centre: Haradoi Hospital Institutional Review Board, Higashiosaka City Medical Center Institutional Review Board, Institutional Review Board of Tokyo Medical University Hachioji Medical Center, International University of Health and Welfare Institutional Review Board, Juntendo University Hospital Institutional Review Board, Kantorosai Hospital Institutional Review Board, Kobori Central Clinical Research Ethics Committee, Koseiren Hospital Central Institutional Review Board, Mishuku Hospital Institutional Review Board, National Hospital Organization Kanazawa Medical Center Institutional Review Board, Nihon University Hospitals' Joint Institutional Review Board, Okayama City Hospital Institutional Review Board, Review Board of Human Rights and Ethics for Clinical Studies Institutional Review Board, Review Board of Human Rights and Ethics for Clinical Studies Institutional Review Board, Saiseikai Kurihashi Hospital Institutional Review Board, Saitama Medical Center Institutional Review Board, Saitama Prefectural Cardiovascular and Respiratory Center Institutional Review Board, Tachikawa Hospital Institutional Review Board, Tokai University Hospital Group Institutional Review Board, Tokushukai Group Institutional Review Board, Tokyo Medical and Dental University Hospital Institutional Review Board, Tokyo Metropolitan Hiroo Hospital Institutional Review Board, Tokyo Shinagawa Hospital Institutional Review Board, Yokohama Municipal Citizen's Hospital Institutional Review Board, and Yokosuka Kyosai Hospital Institutional Review Board.

Sample size calculation

The objective of this study was to establish superiority of camostat mesilate over placebo in patients with COVID-19 using the time to negative SARS-CoV-2 test as the primary endpoint. Patients were to be randomised 1:1 to either camostat mesilate or placebo using a dynamic allocation procedure with site, age ($\geq 65 vs < 65$ years), and presence/absence of underlying diseases (chronic respiratory disease, chronic kidney disease, diabetes mellitus, hypertension, cardiovascular diseases, obesity [body mass index $\geq 30 \text{ kg/m}^2$]) as allocation factors.

If enrolment became difficult due to convergence of COVID-19, an interim analysis was planned to assess the effectiveness or ineffectiveness at the time by applying Bayesian interim monitoring¹ with the criteria for assessment in the interim and final analyses (**table A**). The criteria for the assessment in the final analysis were kept regardless of whether an interim analysis was performed.

Table A. Criteria for assessing effectiveness/ineffectiveness using the Bayesian posterior probability method

Time of analysis	Criteria for effectiveness	Criteria for ineffectiveness
Interim analysis	Bayesian posterior probability $\ge 97.5\%$ for hazard ratio >1.0	Bayesian posterior probability ≤2.5% for hazard ratio >1.0 AND
		Bayesian posterior probability $\geq 80.0\%$ for hazard ratio < 1.4
Final analysis	Bayesian posterior probability $\geq 92\%$ for hazard ratio ≥ 1.0	Bayesian posterior probability $\leq 8\%$ for hazard ratio >1.0

The time to negative SARS-CoV-2 test was assumed to follow an exponential distribution, with a median time of 14 days in the placebo group and a median time of 7–8 days in the camostat mesilate group. The probabilities of meeting the assessment of effectiveness or ineffectiveness with 50 subjects per group (100 in total) were calculated at various analysis time-points by applying numerical simulations in SAS version 9.4. Because the timing of the interim analysis was dependent on the status of the COVID-19 outbreak, numerical simulations were performed, assuming the time-points when 40 to 80 subjects would have been randomised. The prior distribution of the regression coefficient was assumed to be uniform. The numerical experiments were repeated 1,000 times under these conditions, and the probabilities of meeting the assessment of effectiveness at various time points were estimated as shown in **table B**.

Table B. Simulated effectiveness and ineffectiveness rates according to predicted time to time to negative SARS-CoV-2 and number of patients

Median time (days) in the camostat mesilate group	Number of patients at the time of the interim analysis	Assessment	Interim analysis (%)	Final analysis (%)	Total (%)
7	40	Effective	36.6	52.2	88.8
,	10	Ineffective	4.3	6.9	11.2
	50	Effective	44.1	46.2	90.3
		Ineffective	2.4	7.3	9.7
	60	Effective	51.1	39.1	90.2
		Ineffective	2.2	7.6	9.8
	70	Effective	57.5	32.5	90.0
		Ineffective	1.5	8.5	10.0
	80	Effective	64.3	25.9	90.2
		Ineffective	1.5	8.3	9.8
8	40	Effective	23.1	52.2	75.3
		Ineffective	7.6	17.1	24.7
	50	Effective	29.8	45.5	75.3
		Ineffective	6.5	18.2	24.7
	60	Effective	36.1	40.6	76.7
		Ineffective	6.1	17.2	23.3
	70	Effective	39.1	38.0	77.1
		Ineffective	4.6	18.3	22.9
	80	Effective	45.5	31.1	76.6
		Ineffective	4.9	18.5	23.4
14	40	Effective	2.4	6.9	9.3
		Ineffective	43.6	47.1	90.7
	50	Effective	2.6	6.6	9.2
		Ineffective	47.2	43.6	90.8
	60	Effective	2.8	6.4	9.2
		Ineffective	49.2	41.6	90.8
	70	Effective	2.2	6.8	9.0
		Ineffective	53.7	37.3	91.0
	80	Effective	2.3	6.2	8.5
		Ineffective	56.0	35.5	91.5

Based on the numerical experiment, irrespective of which time-point the interim analysis was performed, the probability that treatment would be effective was 75% to 90% if the median duration was 7 or 8 days in the camostat mesilate group. Moreover, if the median duration was 14 days, the probability that treatment was effective was controlled within 10%. From these data, we therefore considered it was possible to demonstrate superiority of camostat mesilate over placebo with a sample size of 100 patients (50 patients per group).

Reference

1. Teramukai S. Bayesian design of single-arm clinical trials with binary endpoints: a review. *Jpn J Biometrics* 2008; **29**: 111–24. In Japanese

Table S1. Discontinuation criteria

No.	Criterion
1	The patient requested to withdraw from the study
2	The patient's representative requested to withdraw the patient from the study
3	The patient did not meet the inclusion criteria or met the exclusion criteria
4	Continuation of the study was considered difficult because of adverse event(s), whether or not related to the study drug, in the opinion of the investigator or subinvestigator
5	The patient tested negative for SARS-CoV-2 on two consecutive occasions
6	If criteria <i>a</i> and <i>b</i> are both met, and continuation of the study was considered difficult: a. Exacerbation of pneumonia was observed by chest imaging b. Oxygen saturation was ≤93% despite oxygen therapy
7	The patient received a prohibited concomitant medication
8	The patient died
9	The patient was found to be pregnant
10	Continuation of the study was not appropriate for any other reason(s), in the opinion of the investigator or subinvestigator

Patient state	Description	Grade
Uninfected	- No clinical or virological evidence of infection	0
Ambulatory	- No limitation of activities	1
	- Limitations of activities	2
Hospitalised		
Mild disease	- Hospitalised, no oxygen therapy	3
	- Oxygen therapy with a mask or nasal prongs	4
Severe disease	- Non-invasive ventilation or high-flow oxygen therapy	5
	- Intubation and mechanical ventilation	6
	- Ventilation and additional organ support (e.g., pressors, renal replacement therapy, extracorporeal membrane oxygenation)	7
Dead	- Death	8

Table S2. Ordinal scale of severity¹

1 World Health Organization R&D Blue Print Team. WHO R&D Blueprint: Novel Coronavirus - COVID-19 Therapeutic Trial Synopsis. Available at: https://www.who.int/publications/i/item/covid-19-therapeutic-trialsynopsis. Accessed: July 22, 2021

Table S3. Events and reasons for	censoring natients for the anal	lysis of time to SARS-CoV-2 negativity
Table 55. Events and reasons for	consoring patients for the anal	ysis of third to SARS-Cov-2 negativity

Status	Event or censored date	Result
SARS-CoV-2 negativity was determined	Sampling date of the sample tested negative for the first time for the SARS-CoV-2 test (measured at the study site)	Event
SARS-CoV-2 negativity was not determined	Sampling date of the last assessable SARS-CoV-2 test (measured at the study site)	Censored
Died	Day 14	Censored
The patient met criteria for discontinuing the study drug (study drug discontinuation criteria 6 or 7) for worsening of COVID-19, and administration of the study drug was discontinued	Day 14	Censored
Study was being discontinued	Sampling date of the last assessable SARS-CoV-2 test (measured at the study site)	Censored
SARS-CoV-2 test (measured at the study site) was not performed more than once after randomisation	Day 1	Censored

Table S4. Events and reasons for censoring patients in the sensitivity analysis of the time to SARS-CoV-2 negativity

Status	Event or censored date	Result
Patient tested negative for SARS-CoV-2, and did not test positive for SARS-CoV-2 thereafter	Sampling date of the sample tested negative for the first time for the SARS-CoV-2 test (measured at the study site)	Event
There were several determinations of SARS-CoV-2 negativity	Sampling date of the sample tested negative for the first time for the SARS-CoV-2 test at the latest determination (measured at the study site).	Event
Patient tested positive for SARS-CoV-2 after a negative test for SARS-CoV-2	Sampling date of the last assessable SARS-CoV-2 test (measured at the study site)	Censored
SARS-CoV-2 negativity was not determined	Sampling date of the last assessable SARS-CoV-2 test (measured at the study site)	Censored
Died	Day 14	Censored
The patient met criteria for discontinuing the study drug (study drug discontinuation criteria 6 or 7) for worsening of COVID-19, and administration of the study drug was discontinued	Day 14	Censored
Study was being discontinued	Sampling date of the last assessable SARS-CoV-2 test (measured at the study site)	Censored
SARS-CoV-2 test (measured at the study site) was not performed more than once after randomisation	Day 1	Censored

Table S5. Changes to the statistical analyses plan from the protocol

Description in the protocol	Description in the statistical analysis plan	Reason for change
None	9 Primary efficacy endpoint9.3 Analysis methodsAddition of sensitivity analysis	To investigate the effect of patients who tested positive for SARS-CoV-2 test after their SARS-CoV-2 test became negative
10.5.5 Secondary efficacy endpoint 10.5.5.2.1 Analysis item Percentage of patient with a negative SARS-CoV-2	10 Secondary efficacy endpoints 10.2 Analysis items and data handling Cumulative proportion of patient with a negative SARS-CoV-2	Based on the definition of the determination of negative conversion and the status of data collection after the determination of negative conversion. To evaluate effectiveness in more detail
None	10 Secondary efficacy endpoints 10.3 Analysis methods Addition of summary statistics to the ordinal scale of severity	To evaluate effectiveness in more detail
10.5.5 Secondary efficacy endpoint 10.5.5.3 Analysis method Analysis method for survival	10 Secondary efficacy endpoints 10.3 Analysis methods Only events, number of censored patients, reasons for censoring, and Kaplan–Meier curves were analysed for survival.	Data on survival status were confirmed in a blinded manner, and detailed analysis was considered unnecessary
None	11 Exploratory efficacy endpoints 11.2 Analysis items and data handling Time to onset of clinical symptoms and addition of the proportion of patients with clinical symptoms	To evaluate effectiveness in more detail
None	11 Exploratory efficacy endpoints 11.3 Analysis methods The addition of an analysis of the difference in the proportion between the treatment groups to the presence or absence of lung lesions in chest images, the proportion of patients in whom clinical symptoms disappeared, and the proportion of patients in whom clinical symptoms occurred	To evaluate effectiveness in more detail
8.2.5.2 Laboratory tests Haematological examination	 12.2 Analysis items and data handling 1) Analysis item (2) Laboratory test: haematological examination Add total neutrophil count 	Because some facilities could not measure the segmented and stab cells separately, an additional item was added to sum the segmented and stab cells

Table S6. Patient disposition

	Camostat mesilate (N = 78)	Placebo (N = 77)	Total (N = 155)
At the end of the observation period			
Number of patients who discontinued or dropped out	0	0	0
At the end of the treatment period			
Number of patients who discontinued or dropped out	68 (87.2)	66 (85.7)	134 (86.5)
Reason for discontinuation or dropout			
Withdrawn at the patient's request	7 (9.0)	6 (7.8)	13 (8.4)
Withdrawn at the guardian's request	0	0	0
Adverse event	2 (2.6)	0	2 (1.3)
Physician's decision	9 (11.5)	11 (14·3)	20 (12.9)
Protocol deviation	0	0	0
Pregnancy	0	0	0
Lost to follow-up	0	0	0
Non-compliance with study drug	0	0	0
Study terminated by sponsor	0	0	0
Death	0	0	0
Protocol-specified withdrawal criterion met	47 (60·3)	48 (62.3)	95 (61.3)
Discontinuation criterion 5	45 (57.7)	43 (55.8)	88 (56.8)
Discontinuation criterion 6	2 (2.6)	5 (6.5)	7 (4.5)
Other	3 (3.8)	1 (1·3)	4 (2.6)
At the end of the study			
Number of patients who discontinued or dropped out	3 (3.8)	5 (6.5)	8 (5.2)
Reason for discontinuation or dropout			
Withdrawn at the patient's request	1 (1·3)	1 (1.3)	2 (1.3)
Withdrawn at the guardian's request	0	0	0
Adverse event	0	0	0
Death	0	1 (1.3)	1 (0.6)
Pregnancy	0	0	0
Other	2 (2.6)	3 (3.9)	5 (3.2)

Values are n (%)

	Camostat mesilate	Placebo
	(N = 74)	(N = 74)
Negative conversion, n (%)	42 (56.8)	45 (60.8)
Number of censored patients, n (%)	32 (43·2)	29 (39·2)
Reasons for censoring patients, n (%)		
The patient tested positive for SARS-CoV-2 after a negative test for SARS-CoV-2	3 (9.4)	2 (6.9)
SARS-CoV-2 negativity was not confirmed	27 (84.4)	21 (72·4)
Death	0	1 (3.4)
The patient met criteria for discontinuing the study drug (study drug discontinuation criteria 6 or 7) for worsening of COVID-19, and administration of the study drug was discontinued	2 (6·3)	4 (13.8)
Patient discontinued the study	0	0
SARS-CoV-2 test (measured at the study site) was not performed more than once after randomisation	0	1 (3·4)
Analysis of time (in days) to a negative test		
Median time (95% confidence interval) ^a	12.0 (10.0-13.0)	11.0 (10.0–13.0)
25 th to 75 th percentile ^a	8·0–n/c	8·0-n/c
Range	2-15+	1+-14+
Main analysis (Bayesian analysis)		
Posterior average of hazard ratio (two-sided 95% credible interval) ^b	0.96 (0.57–1.36)	
Posterior probability that the hazard ratio exceeds 1.0 ^b	38.0	
Secondary analysis (frequency analysis)		
Stratified log-rank test ^e	p = 0.71	
Hazard ratio (95% confidence interval) ^b	0.94 (0.61–1.43)	

Table S7. Results of the sensitivity analysis of the primary endpoint

+, censored; n/c, not calculable

^aEstimated using the Kaplan–Meier method. The Brookmeyer and Crowley method with double log transformation was used to calculate the confidence interval

^bRandomisation factors (age [\geq 65 years) and presence of underlying diseases [chronic respiratory disease, chronic kidney disease, diabetes mellitus, hypertension, cardiovascular disease, and obesity (BMI \geq 30 kg/m²)]) were estimated using a stratified Cox proportional hazards model with stratification factors and treatment group as covariates

 $^{\circ}$ Stratified log-rank test with randomisation factors (age [\geq 65 years vs < 65 years] and presence of underlying diseases [chronic respiratory disease, chronic kidney disease, diabetes mellitus, hypertension, cardiovascular disease, obesity (BMI \geq 30 kg/m²)]) as stratification factors

Camostat mesilate	Placebo
(N = 73)	(N = 72)
30 (41.1)	30 (41.7)
43 (58.9)	42 (58.3)
39 (90.7)	33 (78.6)
0	1 (2·4)
2 (4.7)	3 (7.1)
0	0
2 (4.7)	5 (11.9)
12·0 (10·0–n/c)	12·0 (10·0–n/c)
9·0–n/c	9·0-n/c
1+-15+	1+-14+
	•
0.86 (0.45–1.31)	
23.8	
p = 0.51	
0.83 (0.50–1.39)	
	(N = 73) 30 (41·1) 43 (58·9) 39 (90·7) 0 2 (4·7) 12·0 (10·0-n/c) 9·0-n/c 1+-15+ 0·86 (0·45 23·8 p = 0·

Table S8. Time to negative SARS-CoV-2 status as measured at the central laboratory

+, censored; n/c, not calculable

^aEstimated using the Kaplan-Meier method. The Brookmeyer and Crowley method with double log transformation was used to calculate the confidence interval

^bRandomisation factors (age [\geq 65 years) and presence of underlying diseases [chronic respiratory disease, chronic kidney disease, diabetes mellitus, hypertension, cardiovascular disease, and obesity (BMI \geq 30 kg/m²)]) were estimated using a stratified Cox proportional hazards model with the stratification factors and treatment group as covariates

^cStratified log-rank test with randomisation factors (age [\geq 65 years *vs* <65 years] and presence of underlying diseases [chronic respiratory disease, chronic kidney disease, diabetes mellitus, hypertension, cardiovascular disease, and obesity (BMI \geq 30 kg/m²)]) as stratification factors

able 59. Results of the subgr	oup analyses of the	ie to negative SARS-Co			
Characteristic			Camostat mesilate (N = 74)	Placebo (N = 74)	
Age (years)	≥65	Number of events	15 (51.7)	15 (53.6)	
		Number censored	14 (48.3)	13 (46.4)	
		Median (95% CI) ^a	12.0(9.0-n/c)	13.0(10.0-n/c)	
		Hazard ratio (95% CI)	1.05 (0.5	51-2.16)	
	<65	Number of events	30 (66.7)	32 (69.6)	
		Number censored	15 (33.3)	14 (30.4)	
		Median (95% CI) ^a	11.0 (8.0–12.0)	11.0 (8.0–12.0)	
		Hazard ratio (95% CI)	0.94 (0.5		
Age (years)	≥75	Number of events	7 (53.8)	5 (38.5)	
rige (Jeuis)	_/5	Number censored	6 (46.2)	8 (61.5)	
		Median (95% CI) ^a	10.5 (8.0-n/c)	n/c (9.0-n/c)	
		Hazard ratio	2.03 (0.6		
	≥65 to <75	Number of events	8 (50.0)	10 (66.7)	
	_05 10 475	Number censored	8 (50.0)	5 (33.3)	
		Median (95% CI) ^a	12.0(9.0-n/c)	10.0 (8.0–13.0)	
		Hazard ratio	0.64 (0.2		
	<65	Number of events	30 (66.7)	32 (69.6)	
	<03				
		Number censored	$15(33\cdot3)$	14 (30.4)	
		Median (95% CI) ^a	11.0 (8.0–12.0)	11.0 (8.0–12.0)	
$\mathbf{D}\mathbf{M}(\mathbf{d}_{1} \mid 2)$	> 20	Hazard ratio (95% CI)	0.94 (0.5		
BMI (kg/m ²)	≥30	Number of events	6 (66.7)	4 (66.7)	
		Number censored	3 (33·3)	2 (33·3)	
		Median (95% CI) ^a	11.0(2.0-n/c)	13.0(11.0-n/c)	
		Hazard ratio (95% CI)	2.11 (0.5)	
	<30	Number of events	39 (60.0)	43 (63.2)	
		Number censored	26 (40.0)	25 (36.8)	
		Median (95% CI) ^a	11.0 (9.0–13.0)	11.0 (9.0–13.0)	
		Hazard ratio (95% CI)	0.91 (0.5		
Chronic respiratory disease	Yes	Number of events	7 (63.6)	8 (61.5)	
		Number censored	4 (36·4)	5 (38.5)	
		Median (95% CI) ^a	10.0 (3.0-n/c)	12·0 (7·0–n/c)	
		Hazard ratio (95% CI)	1.50 (0.4		
	No	Number of events	38 (60.3)	39 (63.9)	
		Number censored	25 (39.7)	22 (36.1)	
		Median (95% CI) ^a	11.0 (9.0–13.0)	11.0 (9.0–13.0)	
		Hazard ratio (95% CI)	0.93 (0.5	59–1·46)	
Chronic kidney disease	Yes	Number of events	4 (80.0)	2 (50.0)	
-		Number censored	1 (20.0)	2 (50.0)	
		Median (95% CI) ^a	9.0 (2.0-12.0)	n/c (9·0–n/c)	
		Hazard ratio (95% CI)	71016179-2	3(0.00-n/c)	
	No	Number of events	41 (59.4)	45 (64.3)	
		Number censored	28 (40.6)	25 (35.7)	
		Median (95% CI) ^a	11.0 (10.0–13.0)	11.0 (10.0–12.0)	
		Hazard ratio (95% CI)	0.91 (0.5		
Diabetes mellitus	Yes	Number of events	10 (71.4)	5 (41.7)	
		Number censored	4 (28.6)	7 (58.3)	
		Median (95% CI) ^a	9.0 (5.0–10.0)	n/c (8.0-n/c)	
		Hazard ratio (95% CI)	3.78 (1.0		
	No	Number of events	35 (58.3)	42 (67.7)	
	110	Number censored	25 (41.7)	20 (32.3)	
		Median (95% CI) ^a	12.0(10.0-14.0)	11.0 (10.0–13.0)	
		Hazard ratio(95% CI)	0.78 (0.5		
Urmantanaian	V		· · · · · · · · · · · · · · · · · · ·		
Hypertension	Yes	Number of events	14(60.9)	9 (47·4)	
		Number censored	9 (39.1)	10(52.6)	
		Median (95% CI) ^a	11.0 (9.0-n/c)	13.0 (9.0-n/c)	
) Y	Hazard ratio (95% CI)	1.16 (0.4		
	No	Number of events	31 (60.8)	38 (69.1)	
		Number censored	20 (39.2)	17 (30.9)	
	1	Median (95% CI) ^a	11.0 (9.0–13.0)	11.0 (9.0–13.0)	
		Hazard ratio (95% CI)	0.87 (0.5	/	
Cardiovascular disease	Yes	Hazard ratio (95% CI) Number of events	1 (25.0)	1 (25.0)	
Cardiovascular disease	Yes	Hazard ratio (95% CI)		/	

Table S9. Results of the subgroup analyses of time to negative SARS-CoV-2 status

Characteristic			Camostat mesilate (N = 74)	Placebo $(N = 74)$
		Hazard ratio (95% CI)	1.00 (1.0	00-1.00)
	No	Number of events	44 (62.9)	46 (65.7)
		Number censored	26 (37.1)	24 (34.3)
		Median (95% CI) ^a	10.0 (9.0-12.0)	11.0 (10.0-12.0)
		Hazard ratio (95% CI)	0.93 (0.6	52-1.42)
Time (days) from sample collection date to	<4	Number of events	29 (72.5)	15 (46.9)
confirmation of SARS-CoV-2 positive status		Number censored	11 (27.5)	17 (53.1)
in patients who were asymptomatic at the		Median (95% CI) ^a	10.0 (9.0-12.0)	13.0(10.0-n/c)
registration date		Hazard ratio (95% CI)	1.76 (0.9	
	≥4	Number of events	16 (47.1)	32 (76.2)
	_	Number censored	18 (52.9)	10 (23.8)
		Median (95% CI) ^a	13.0 (9.0 - n/c)	10.0 (9.0–12.0)
		Hazard ratio (95% CI)	0.56 (0.3	
SARS-CoV-2 viral load (central testing)	<7	Number of events	26 (74.3)	33 (76.7)
(log ₁₀ copies/mL)		Number censored	9 (25.7)	10 (23.3)
		Median (95% CI) ^a	9.0 (8.0-9.0)	10.0 (8.0–12.0)
		Hazard ratio (95% CI)	1.15 (0.6	
	≥7	Number of events	19 (48.7)	14 (45.2)
		Number censored	20 (51.3)	17 (54.8)
		Median (95% CI) ^a	13.0 (12.0-n/c)	13·0 (10·0–n/c)
		Hazard ratio (95% CI)	0.92 (0.4	
Presence of pulmonary lesions	Yes	Number of events	23 (63.9)	27 (67.5)
j		Number censored	13 (36.1)	13 (32.5)
		Median (95% CI) ^a	10.0 (8.0–12.0)	11.0 (8.0–13.0)
		Hazard ratio (95% CI)	1.05 (0.6	(/
	No	Number of events	22 (57.9)	20 (58.8)
	110	Number censored	16 (42.1)	14 (41.2)
		Median (95% CI) ^a	12.0 (10.0–14.0)	12.0 (10.0–13.0)
		Hazard ratio (95% CI)	0.86 (0.4	120(100150)
IgM antibody test (central testing)	Positive	Number of events	1 (100.0)	1 (50.0)
ight analoug test (contait testing)	1 contro	Number censored	0 (0.0)	1 (50.0)
		Median (95% CI) ^a	11.0 (n/c-n/c)	$\frac{n/c}{(2.0-n/c)}$
		Hazard ratio (95% CI)	1.00 (1.0	
	Negative	Number of events	44 (60.3)	46 (63.9)
	reguire	Number censored	29 (39.7)	26 (36.1)
		Median (95% CI) ^a	11.0 (9.0–13.0)	11.0 (10.0–13.0)
		Hazard ratio (95% CI)	0.96 (0.6	
IgG antibody test (central testing)	Positive	Number of events	1 (100.0)	0
igo annoody tost (contait tosting)	1 contro	Number censored	0	0
		Median (95% CI) ^a	2.0 (n/c-n/c)	n/c (n/c–n/c)
		Hazard ratio (95% CI)	n/c (n/	· /
	Negative	Number of events	44 (60.3)	47 (63.5)
	reguire	Number censored	29 (39.7)	27 (36.5)
		Median (95% CI) ^a	11.0 (9.0–12.0)	11.0 (10.0–13.0)
		Hazard ratio (95% CI)	0.95 (0.6	
Presence of clinical symptom(s)	Yes	Number of events	37 (69.8)	36 (69.2)
resence of enhieur symptom(s)	100	Number censored	16 (30.2)	16 (30.8)
		Median (95% CI) ^a	10.0 (9.0–12.0)	11.0 (10.0–13.0)
		Hazard ratio	10.0 (9.0–12.0)	
	No	Number of events	8 (38.1)	11 (50.0)
	INU			
		Number concored		
		Number censored Median (95% CI) ^a	13 (61·9) n/c (9·0–n/c)	$\frac{11 (50.0)}{12.0 (8.0-n/c)}$

CI, confidence interval; n/c, not calculable; BMI, body mass index; Ig, immunoglobulin ^aEstimated using the Kaplan–Meier method



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	ltem No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	5
Introduction			
Background and	2a	Scientific background and explanation of rationale	6-7
objectives	2b	Specific objectives or hypotheses	7
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	8-9
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Protocol
Participants	4a	Eligibility criteria for participants	8, Protocol
	4b	Settings and locations where the data were collected	8
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	8-10
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	10-11, Protocol
	6b	Any changes to trial outcomes after the trial commenced, with reasons	Protocol
Sample size	7a	How sample size was determined	11-12, appendix sample
			size calculation
	7b	When applicable, explanation of any interim analyses and stopping guidelines	11, Protocol
Randomisation:			
Sequence	8a	Method used to generate the random allocation sequence	9, Protocol
generation	8b	Type of randomisation; details of any restriction (such as blocking and block size)	9, Protocol
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	9, Protocol

Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned	9, Protocol
		participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	8-13, Protocol
	11b	If relevant, description of the similarity of interventions	9-10
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	11-13, Protocol
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	11-13, Protocol
Results			
Participant flow (a diagram is strongly	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	15-16, Table S6
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	15, figure 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	15
	14b	Why the trial ended or was stopped	15
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	15-17, tables, figures
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	15-17, tables, figures
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	15-17, tables, figures
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses,	16-17, Appendix tables S7
		distinguishing pre-specified from exploratory	S9
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	17, table 3
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	20
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	19-21
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	21
Other information			
Registration	23	Registration number and name of trial registry	13
Protocol	24	Where the full trial protocol can be accessed, if available	Journal website
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	14

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see <u>www.consort-statement.org</u>.